RS BioTherapeutics Inc. — Form D
RS BioTherapeutics Inc. of CUMBERLAND, MD, a company, filed a Form D exempt-offering notice with the SEC on 2023-03-22. The offering totals $10.0M, of which $100K was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2023-03-22
- Form: D
- Accession: 0001932193-23-000001
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $10.0M
- Amount sold: $100K
- Remaining: $9.9M
- Minimum investment: $50K
- Investors: 1
- Date of first sale: 2022-11-16
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-476630
Issuer
- Name: RS BioTherapeutics Inc.
- CIK: 0001932193
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 157 BALTIMORE STREET, CUMBERLAND, MD, 21502
- Phone: 717.433.5390
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| Dustin Dean Freas | Director | Cumberland, MD |
| Curtis Dean Rhine | Executive Officer | Cumberland, MD |
| Michael Dean Guzman | Executive Officer | Cumberland, MD |
| H. Dean Hart | Executive Officer | Cumberland, MD |
| Curtis Rhine | Executive Officer | Cumberland, MD |
| Justin Dean Molignoni | Director | Cumberland, MD |
| Justin Dean Molignoni | Executive Officer | Cumberland, MD |
| David Dean Freas | Director | Cumberland, MD |
| Dustin Dean Freas | Executive Officer | Cumberland, MD |
Other filings by this issuer (4)
More